Vixarelimab  (Synonyms: KPL-716)

Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash^[1].

IgG4-G1-lambda2

Human IgG4 (S228P) kappa, Isotype Control

Human

OSMR

Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) results in increased MCP-1/CCL2 levels at a concentration of 0.0001 μg/mL in human epidermal keratinocytes (HEK) and human dermal fibroblasts (HDF) cells and a significant decrease in MCP-1/CCL2 levels in both cells at concentrations of 0.001 μg/mL or higher^[1].
Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) pretreatment results in reduced levels of MCP-1/CCL2 in both Oncostatin M (OSM) induced as well as OSM plus IL-4 induced HEK and HDF cells and the maximum effect is observed at concentrations of 0.01 μg/mL and 0.1 μg/mL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

9180  [NCBI]

Q99650

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.042 kDa

2243320-83-2

Liquid

Colorless to light yellow

[Vixarelimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG4-G1-lambda2

• 
  Flow Cytometry analysis of Hela cells labelling OSMR (red) with Vixarelimab (anti-OSMR) (HY-P99519). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Carl D Richards, et al. Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716. Acta Derm Venereol. 2020 Jul 2;100(14):adv00197.  [Content Brief]